Compare Fortinet Inc (FTNT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Twist Bioscience Corp — how do they compare? Fortinet Inc trades at $161.78 (market cap $120.53B), while Twist Bioscience Corp trades at $90.24 (market cap $5.76B). The key difference: Fortinet Inc is far larger — about 20.9× Twist Bioscience Corp's market cap, and Fortinet Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals.
| FTNT | TWST | |
|---|---|---|
Market Cap | $120.53B | $5.76B |
Sector | Technology | Health |
52-Week High | $166.83 | $102.88 |
52-Week Low | $74.39 | $24.16 |
Enterprise Value | $117.73B | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $161.46, down 3.22% today, but maintains a bullish technical signal with strong moving averages and support near $162. The company reported consistent earnings beats, with Q1 2026 EPS of $0.82 surpassing the $0.619 estimate, and demonstrates robust fundamentals including 80.3% gross margins and 27.49% net income margin. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with Fortinet expanding its FortiEndpoint platform for AI security (GlobeNewsWire, July 14, 2026).
Outlook is positive due to AI cybersecurity tailwinds and earnings momentum, but high valuation ratios (P/E of 63.76, P/S of 17.5) pose risks if growth slows. Analyst consensus is mixed with 42.65% buy ratings, though the $123.16 price target suggests caution relative to current levels. Key risks include competitive pressures and reliance on enterprise IT spending cycles.
Twist Bioscience (TWST) trades at $90.33, down 2.46% on the day, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst sentiment is positive with 11 buy ratings and a $91.63 consensus target, while recent news highlights AI collaborations and upcoming Q3 earnings.
TWST presents a growth story with improving margins and AI-driven demand, but profitability concerns and consistent cash burn pose risks. The stock trades near analyst targets, suggesting limited near-term upside without earnings acceleration. Key catalysts include Q3 results on August 3, 2026, and execution on path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
